BioMarin Pharmaceutical – CLN2 Disease

Access Program Information

– To provide access to BMN 190 to patients with CLN2 disease who cannot participate in a
clinical trial.

– To collect additional information on the safety and tolerability of BMN 190
administration in patients with CLN2 disease.